Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences

SAN FRANCISCO--(BUSINESS WIRE)--Jan 12, 2026--

Owkin, an AI company on a mission to solve the complexity of biology, today announced that its interoperable Pathology Explorer AI agent will be included in the launch of Claude for Healthcare and Life Sciences (HCLS) by Anthropic. This marks the first time a highly specialized, world-leading biological agent trained primarily on multimodal patient data is accessible through the Model Context Protocol (MCP) to a broad audience of healthcare and life sciences professionals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112836381/en/

The collaboration enables seamless integration of Owkin's advanced pathology analysis capabilities into Claude's AI platform, making sophisticated biological intelligence accessible to healthcare organizations, pharmaceutical companies, and research institutions within their Claude workflows, without requiring system overhauls or proprietary process changes.

"I believe this agentic interoperability is the future of biopharma discoveries," said Thomas Clozel, M.D., CEO and co-founder of Owkin. "By making our best-in-class agents trained on patient data from the world's leading hospitals accessible through portals like Claude for HCLS, we're enabling the biggest healthcare organizations to accelerate their research in ways that weren't possible before. This is about putting patient data first when training AI and making that intelligence universally available to cure disease faster."

Pathology Explorer is part of Owkin’s K Pro community of agents for biology. This agent identifies and locates cell and tissue types, enabling spatially-aware analysis of patient tissue images. Using the agent, users can analyze tumors and their microenvironments and study inflammation patterns. Pathology Explorer enables the extraction of biomarkers from digitized pathology images to generate and validate hypotheses through cohort-level survival analysis — a critical capability for accelerating drug discovery, clinical trial design, and development of digital diagnostic tools. The agent leverages proprietary, best-in-class AI models that have been trained on patient histopathology data sourced from Owkin's network spanning over 800 hospitals from 104 healthcare centers, enabling it to deliver high-accuracy analysis.

Owkin MCP Integration Enables Seamless Access

Owkin has developed industry standard MCP encoding specifically designed to allow its proprietary K Pro agents to integrate seamlessly with Claude's interface. Pathology Explorer is the first agent from Owkin's interoperable agentic AI infrastructure for biology to be offered for external integration, demonstrating the company's commitment to building an open, API-first infrastructure that can serve as the universal foundation for advancing drug development.

Claude for Healthcare and Life Sciences is designed to accelerate preclinical R&D (including bioinformatics, protocol development, and literature synthesis), streamline clinical trial operations and data management, and support regulatory affairs and submission preparation. The integration of Owkin's Pathology Explorer extends these capabilities by enabling deep biological reasoning specifically trained on real patient data.

This is the third in a series of major announcements Owkin is unveiling, including agentic infrastructure for biology (Owkin's new interoperable agentic infrastructure for biopharma) and a strategic collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model.

About Owkin

Owkin is an AI company with $300 million in funding on a mission to solve the complexity of biology. It is building the first Biological Artificial Super Intelligence (BASI) by combining powerful biological large reasoning models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot, and OwkinZero, Owkin's biological large reasoning model, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster. Owkin has exclusive access to multimodal patient data from more than 800 hospitals collected over a decade and partners with eight of the 10 largest pharmaceutical companies. For more information, visit www.owkin.com.

Owkin Media Kit:https://www.owkin.com/press-kit

Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences.

DETROIT (AP) — President Donald Trump will travel to Michigan on Tuesday to promote his efforts to boost U.S. manufacturing, trying to counter fears about a weakening job market and worries that still-rising prices are taking a toll on Americans' pocketbooks.

The day trip will include a tour of a Ford factory in Dearborn that makes F-150 pickups, the bestselling domestic vehicle in the U.S. The president is also set to address the Detroit Economic Club at the MotorCity Casino.

November's off-year elections in Virginia, New Jersey and elsewhere showed a shift away from Republicans as public concerns about kitchen table issues persist. In their wake, the White House said Trump would put a greater emphasis on talking directly to the public about his economic policies after doing relatively few events around the country earlier in his term.

The president has suggested that jitters about affordability are a “hoax” unnecessarily stirred by Democrats. Still, though he's imposed steep tariffs on U.S. trading partners around the world, Trump has reduced some of them when it comes to making cars — including extending import levies on foreign-made auto parts until 2030.

Ford announced last month that it was scrapping plans to make an electric F-150, despite pouring billions into broader electrification, after the Trump administration slashed targets to have half of all new vehicle sales be electric by 2030, eliminated EV tax credits and proposed weakening the emissions and gas mileage rules.

His Michigan swing follows economy-focused speeches the president gave last month in Pennsylvania — where Trump's gripes about immigrants arriving to the U.S. from “filthy” countries got more attention than his pledges to fight inflation — and North Carolina, where he insisted his tariffs have spurred the economy, despite residents noting the squeeze of higher prices.

Trump carried Michigan in 2016 and 2024, after it swung Democratic and backed Joe Biden in 2020. He marked his first 100 days in office with a rally-style April speech outside Detroit, where he focused more on past campaign grudges than his administration's economic or policy plans.

During that visit nearly nine months ago, Trump also spoke at Selfridge Air National Guard Base and announced a new fighter jet mission, allaying fears that the base could close. It represented a win for Michigan Democratic Gov. Gretchen Whitmer — and the two even shared a hug.

This time, Democrats have panned the president's trip, singling out national Republicans' opposition to extending health care subsidies and recalling a moment in October 2024 when Trump suggested that Democrats' retaining the White House would mean “our whole country will end up being like Detroit."

"You’re going to have a mess on your hands,” Trump said during a campaign stop back then.

Curtis Hertel, chair of the Michigan Democratic Party, said that “after spending months claiming that affordability was a ‘hoax’ and creating a health care crisis for Michiganders, Donald Trump is now coming to Detroit — a city he hates — to tout his billionaire-first agenda while working families suffer."

“Michiganders are feeling the effects of Trump’s economy every day,” Hertel said in a statement.

Weissert reported from Washington.

President Donald Trump speaks to reporters while in flight on Air Force One to Joint Base Andrews, Md., Sunday, Jan. 11, 2026. (AP Photo/Julia Demaree Nikhinson)